Norethindrone Acetate-Ethinyl Estradiol

Phase 1Small molecule

Norethindrone Acetate-Ethinyl Estradiol is one of 5 small molecule programs targeting Arginine Vasopressin Deficiency. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Arginine Vasopressin DeficiencyRecruiting

OxytocinRecruiting

Arginine Vasopressin DeficiencyPhase 1

Recruiting

OxytocinPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Oxytocin

#DrugCompanyPhaseTrials

Pitocin

RRetrophin

Approved

108 2

Intranasal Oxytocin

UUniversity of Electronic Science and Technology of China

Phase 2

18 3

Half-Dose Oxytocin

NNorthwestern University

Phase 3

2 4

Pitressin

AAultman Health Foundation

Preclinical

1 5

Norethindrone Acetate-Ethinyl Estradiol

EElizabeth Austen Lawson

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Arginine Vasopressin Deficiency

NCT07568509

Clinical

Trials by Indication[1]

Oxytocin1 trial

Identifying Oxytocin Deficiency in Adults With Pituitary Disease

Recruiting·EElizabeth Austen Lawson·Phase 1·NCT06460948·32 enrolled

Arginine Vasopressin Deficiency1 trial

Identifying a Provocation Test for Diagnosis of Oxytocin Deficiency in Youth With Hypopituitarism

Recruiting·MMassachusetts General Hospital·Phase 1·NCT07568509·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Norethindrone Acetate-Ethinyl Estradiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Norethindrone Acetate-Ethinyl Estradiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Norethindrone Acetate-Ethinyl Estradiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Elizabeth Austen Lawson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EElizabeth Austen Lawson

Norethindrone Acetate-Ethinyl Estradiol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Oxytocin1 trial

Arginine Vasopressin Deficiency1 trial

References

Drug Info

Quick Facts

Related News